BZH is likely driven by the transcriptional response of the epithelium to the pro-atopy cytokine IL-13, which is corroborated by in vitro studies and in vivo murine models of EoE (9–11), and importantly by the clinical benefit of blocking IL-13 in patients (12–14). The gene discussed is IL13; the disease is eosinophilic esophagitis.